{
    "2021-12-05": [
        [
            {
                "time": "2021-12-05",
                "original_text": "贝达药业第四代EGFR抑制剂BPI-361175在美国获批临床",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "BPI-361175",
                        "EGFR抑制剂",
                        "美国",
                        "临床试验"
                    ],
                    "sentiment_score": 0.9,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2021-12-05",
                "original_text": "贝达药业：BPI-361175片获美国FDA新药临床试验批准通知书",
                "features": {
                    "keywords": [
                        "贝达药业",
                        "BPI-361175",
                        "FDA",
                        "新药",
                        "临床试验"
                    ],
                    "sentiment_score": 0.85,
                    "policy_related": "false",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "false",
                    "ts_effect_direction": ""
                }
            },
            {
                "time": "2021-12-05",
                "original_text": "医药行业周报：医保谈判尘埃落定，看好本土创新发力",
                "features": {
                    "keywords": [
                        "医药行业",
                        "医保谈判",
                        "本土创新"
                    ],
                    "sentiment_score": 0.75,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "positive",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "positive"
                }
            },
            {
                "time": "2021-12-05",
                "original_text": "医保国谈结果公布，国产四款PD-1仅恒瑞新增适应症未出现",
                "features": {
                    "keywords": [
                        "医保国谈",
                        "PD-1",
                        "恒瑞",
                        "适应症"
                    ],
                    "sentiment_score": -0.6,
                    "policy_related": "true",
                    "investment_strategy": "true",
                    "sector_focus": [
                        "医药"
                    ],
                    "causal_factor": "true",
                    "causal_impact": "negative",
                    "affected_by_time_series": "true",
                    "ts_effect_direction": "negative"
                }
            }
        ]
    ]
}